European Panel Backs Approval of Kyowa Kirin’s Mogamulizumab for Mycosis Fungoides, Sézary Syndrome

Kyowa Hakko Kirin said on September 21 that a key European panel has issued a positive opinion backing approval of its anti-CCR4 monoclonal antibody mogamulizumab, known as Poteligeo, for the treatment of adult patients with mycosis fungoides or Sézary syndrome...read more